公开(公告)号：ES2901173T3

公开(公告)日：2022-03-21

申请号：ES16744256

申请日：2016-01-30

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  MA CHE ,  WU HAN-CHUNG

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30 ,  C12P19/14

Abstract: Anticuerpo monoclonal aislado o un fragmento de unión del mismo que se une a Neu5Acα2 → 3Galβ1 → 3GalNAcβ1 → 3Galα1 → 4Galβ1 → 4Glcβ1 (hexasacárido SSEA-4), en el que el anticuerpo monoclonal aislado o el fragmento de unión del mismo es un anticuerpo desfucosilado que comprende una glicoforma de Fc unida a la región de Fc, en la que dicha glicoforma tiene la fórmula: **(Ver fórmula)** Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2 en la que el anticuerpo comprende una VH que tiene la SEQ ID NO: 147 y una VL que tiene la SEQ ID NO: 148.

公开(公告)号：CA3052909C

公开(公告)日：2021-10-19

申请号：CA3052909

申请日：2013-08-20

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  TSAI TSUNG-I

IPC: C12P19/18 ,  C07H15/04 ,  C12M1/40 ,  C12N9/00 ,  C12N9/10 ,  C12N9/12 ,  C12P19/00 ,  C12P19/04 ,  C12P19/30 ,  C12P19/44

Abstract: A novel UDP-Gal regeneration process and its combined use with a galactosyltransferease to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.

公开(公告)号：DK3245225T3

公开(公告)日：2021-10-18

申请号：DK15878250

申请日：2015-07-13

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  LOU YI-WEI ,  LIN CHIH-WEI ,  WU CHUNG-YI ,  WU HAN-CHUNG ,  YEH SHIH-CHI ,  HSU TSUI-LING

IPC: C07K16/18 ,  A61P35/00 ,  C07K16/30 ,  C12P19/14

公开(公告)号：AU2021200784A1

公开(公告)日：2021-03-04

申请号：AU2021200784

申请日：2021-02-08

Applicant: ACADEMIA SINICA

Inventor： WU CHUNG-YI ,  TSAI MING-HUNG ,  WONG CHI-HUEY

IPC: C07K16/00

Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by FE glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased FE receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：AU2015267045B2

公开(公告)日：2021-02-25

申请号：AU2015267045

申请日：2015-05-27

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI

IPC: C07K16/00

Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：CA2728341C

公开(公告)日：2019-07-02

申请号：CA2728341

申请日：2009-08-06

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  YU ALICE ,  YU JOHN

IPC: A61K39/00 ,  A61K39/385

Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer are provided. Compositions compris-ing: (a) a glycan such as Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein by a linker such as para-nitrophenyl; and (b) an adjuvant comprising glycolipid capable of binding CDId on a dendritic cell, such as an a-galactosyl-ceramide derivative, wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies, are provided. Immunogenic compositions compris-ing the carrier protein diphtheria toxin cross-reacting material 197 (DT-CRM 197) and the adjuvant C34 are provided. Antibodies generated by immunogenic compositions disclosed herein further neutralize at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4). Therapeutics against breast cancer stem cells comprising immunogenic compositions comprising Globo H, SSEA-3 or SSEA-4 conjugated with DT-CRM 197.

公开(公告)号：AU2017231749A1

公开(公告)日：2018-09-20

申请号：AU2017231749

申请日：2017-03-08

Applicant: WONG CHI HUEY ,  ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  SHIVATARE SACHIN S

IPC: C08B37/00 ,  C12P19/04 ,  G01N33/50 ,  G01N33/532 ,  G01N33/68

Abstract: The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycansand glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.

公开(公告)号：CA3016170A1

公开(公告)日：2017-09-14

申请号：CA3016170

申请日：2017-03-08

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  SHIVATARE SACHIN S

IPC: C08B37/00 ,  C12P19/04 ,  G01N33/50 ,  G01N33/532 ,  G01N33/68

Abstract: The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycans and glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.

公开(公告)号：CA2972731A1

公开(公告)日：2016-07-28

申请号：CA2972731

申请日：2016-01-25

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  CHEUNG SARAH K C ,  CHUANG PO-KAI ,  HSU TSUI-LING

IPC: G01N33/574 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

公开(公告)号：CA2972072A1

公开(公告)日：2016-07-28

申请号：CA2972072

申请日：2015-08-21

Applicant: ACADEMIA SINICA

Inventor： WU CHUNG-YI ,  WONG CHI-HUEY

IPC: G01N33/53

Abstract: The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA3/SSEA4/GloboH associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globo-series glycosphingolipid SSEA3/SSEA4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globo-series synthetic pathway. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.